Digital Cognitive Risk Assessment Market Forecasts to 2034 – Global Analysis By Solution Type (Digital Cognitive Screening Platforms, AI-Based Risk Assessment Software, Clinical Decision Support Systems, Digital Biomarker Platforms, Remote Cognitive Monitoring Solutions and Population Risk Assessment Platforms), Technology, Application, End User and By Geography
According to Stratistics MRC, the Global Digital Cognitive Risk Assessment Market is accounted for $1.3 billion in 2026 and is expected to reach $9.6 billion by 2034 growing at a CAGR of 28.5% during the forecast period. Digital cognitive risk assessment refers to technology-enabled evaluation systems designed to identify, quantify, and monitor individual susceptibility to cognitive decline, neurodegenerative disease, and brain-related health complications through automated screening and predictive analytics. These solutions integrate artificial intelligence, digital biomarkers, remote monitoring capabilities, and standardized cognitive testing protocols to detect early signs of impairment before clinical symptoms become apparent. The technology encompasses software-based screening platforms, clinical decision support tools, population health analytics systems, and wearable-integrated monitoring solutions that enable healthcare providers, payers, and researchers to stratify risk and implement targeted preventive interventions.
Market Dynamics:
Driver:
Preventive healthcare shift
The global transformation toward preventive healthcare models is driving substantial demand for digital cognitive risk assessment solutions that enable early identification of dementia and related conditions before irreversible neurological damage occurs. Healthcare payers recognize the cost-saving potential of early intervention compared to late-stage dementia care. Pharmaceutical companies require risk stratification tools to identify appropriate clinical trial participants. Government aging strategies increasingly incorporate cognitive health screening as standard preventive care. These systemic shifts create multiple revenue streams and market stability across clinical, research, and payer segments.
Restraint:
Clinical workflow integration
The challenge of integrating digital cognitive risk assessment tools into existing clinical workflows without adding a significant time burden to healthcare providers limits widespread adoption. Primary care physicians face competing demands during brief patient encounters and may lack training to interpret digital risk scores appropriately. Electronic health record integration requires costly technical development and ongoing maintenance. These operational barriers concentrate market penetration among specialized neurology practices and research institutions with dedicated resources for digital health implementation.
Opportunity:
Insurance reimbursement expansion
The expanding recognition of cognitive screening as a reimbursable preventive service presents significant commercial opportunities for digital cognitive risk assessment providers. Medicare and private insurers increasingly cover annual wellness visits that incorporate cognitive assessment. Value-based care contracts incentivize early identification and management of chronic conditions, including dementia. Partnerships with accountable care organizations create population-level deployment opportunities. These reimbursement trends transform cognitive risk assessment from an optional add-on to a standard care protocol, dramatically expanding the addressable market size.
Threat:
Diagnostic false positives
The risk of false positive cognitive risk assessments generating unnecessary patient anxiety, follow-up testing, and healthcare costs threatens market confidence in digital screening tools. Algorithmic bias in training data may produce inaccurate risk predictions for underrepresented demographic groups. Regulatory scrutiny of health claims for software-based diagnostic tools intensifies as the market expands. These quality and liability concerns create resistance among conservative clinicians and risk-averse healthcare systems, slowing mainstream adoption despite technological capabilities.
Covid-19 Impact:
The COVID-19 pandemic disrupted routine in-person cognitive screening while accelerating the development and deployment of remote digital risk assessment platforms. Healthcare providers required contactless alternatives to maintain preventive care continuity. Post-pandemic, hybrid screening models combining digital remote assessment with targeted in-person follow-up have become standard practice. The crisis also generated significant data on COVID-related cognitive impacts, improving risk models, and increasing public awareness of cognitive health monitoring. Sustained telehealth infrastructure investment supports continued remote assessment capabilities.
The digital cognitive screening platforms segment is expected to be the largest during the forecast period
The digital cognitive screening platforms segment is expected to account for the largest market share during the forecast period, due to their broad accessibility and established integration into primary care and community health settings. These platforms deliver brief, standardized cognitive assessments through tablets, smartphones, and web interfaces that require minimal staff training. Healthcare systems value the efficiency and cost-effectiveness of digital screening compared to traditional neuropsychological evaluation. Population health programs leverage these tools for large-scale dementia risk identification. The scalability of automated scoring and reporting supports enterprise deployment across health networks.
The artificial intelligence segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the artificial intelligence segment is predicted to witness the highest growth rate, driven by its capacity to analyze complex multi-modal data and identify subtle cognitive risk signatures invisible to traditional screening methods. Machine learning models trained on diverse datasets improve detection accuracy for early-stage neurodegenerative conditions. Natural language processing enables analysis of speech patterns for cognitive decline indicators. These AI capabilities significantly enhance screening sensitivity and specificity, reducing false positive rates that plague simpler digital assessments. Regulatory frameworks increasingly accommodate AI-based diagnostic software.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, due to advanced healthcare data infrastructure and established reimbursement for cognitive screening within Medicare annual wellness visits. The United States leads with substantial Alzheimer's research funding, major academic consortia generating large cognitive datasets, and favorable FDA regulatory pathways for software-based medical devices. Healthcare payers actively seek cost-effective early identification tools to manage dementia-related expenditures. Venture capital investment supports continuous innovation in digital cognitive assessment technologies.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly aging populations in China, Japan, and South Korea, creating urgent demand for dementia prevention infrastructure. Government digital health initiatives support technology adoption across public hospital networks. Growing middle-class health awareness drives consumer demand for cognitive health screening. The region's technology ecosystem enables indigenous platform development at competitive price points. Health insurance expansion in emerging markets increases patient access to preventive cognitive assessment services previously unavailable.
Key players in the market
Some of the key players in Digital Cognitive Risk Assessment Market include Cambridge Cognition Holdings plc, Cogstate Ltd., CNS Vital Signs, Creyos Corporation, Philips Healthcare, GE HealthCare, Siemens Healthineers AG, Canon Medical Systems Corporation, FUJIFILM Healthcare, Tempus AI, Verily Life Sciences, Oracle Health, IBM Corporation, Natus Medical Incorporated, Compumedics Limited, EMOTIV Inc. and BrainCo Inc..
Key Developments:
In June 2026, Cambridge Cognition Holdings plc launched a next-generation digital cognitive risk assessment platform featuring AI-driven pattern recognition that identifies subtle preclinical markers of dementia from brief smartphone-based cognitive tests.
In May 2026, Cogstate Ltd. expanded its digital cognitive screening portfolio to include population health analytics capabilities, enabling healthcare systems to identify geographic clusters of elevated dementia risk for targeted intervention deployment.
In April 2026, Creyos Corporation introduced a cloud-based cognitive risk assessment system designed for primary care integration that delivers immediate risk scores and automated referral recommendations based on standardized digital cognitive testing.
Solution Types Covered:
All the customers of this report will be entitled to receive one of the following free customization options:
Market Dynamics:
Driver:
Preventive healthcare shift
The global transformation toward preventive healthcare models is driving substantial demand for digital cognitive risk assessment solutions that enable early identification of dementia and related conditions before irreversible neurological damage occurs. Healthcare payers recognize the cost-saving potential of early intervention compared to late-stage dementia care. Pharmaceutical companies require risk stratification tools to identify appropriate clinical trial participants. Government aging strategies increasingly incorporate cognitive health screening as standard preventive care. These systemic shifts create multiple revenue streams and market stability across clinical, research, and payer segments.
Restraint:
Clinical workflow integration
The challenge of integrating digital cognitive risk assessment tools into existing clinical workflows without adding a significant time burden to healthcare providers limits widespread adoption. Primary care physicians face competing demands during brief patient encounters and may lack training to interpret digital risk scores appropriately. Electronic health record integration requires costly technical development and ongoing maintenance. These operational barriers concentrate market penetration among specialized neurology practices and research institutions with dedicated resources for digital health implementation.
Opportunity:
Insurance reimbursement expansion
The expanding recognition of cognitive screening as a reimbursable preventive service presents significant commercial opportunities for digital cognitive risk assessment providers. Medicare and private insurers increasingly cover annual wellness visits that incorporate cognitive assessment. Value-based care contracts incentivize early identification and management of chronic conditions, including dementia. Partnerships with accountable care organizations create population-level deployment opportunities. These reimbursement trends transform cognitive risk assessment from an optional add-on to a standard care protocol, dramatically expanding the addressable market size.
Threat:
Diagnostic false positives
The risk of false positive cognitive risk assessments generating unnecessary patient anxiety, follow-up testing, and healthcare costs threatens market confidence in digital screening tools. Algorithmic bias in training data may produce inaccurate risk predictions for underrepresented demographic groups. Regulatory scrutiny of health claims for software-based diagnostic tools intensifies as the market expands. These quality and liability concerns create resistance among conservative clinicians and risk-averse healthcare systems, slowing mainstream adoption despite technological capabilities.
Covid-19 Impact:
The COVID-19 pandemic disrupted routine in-person cognitive screening while accelerating the development and deployment of remote digital risk assessment platforms. Healthcare providers required contactless alternatives to maintain preventive care continuity. Post-pandemic, hybrid screening models combining digital remote assessment with targeted in-person follow-up have become standard practice. The crisis also generated significant data on COVID-related cognitive impacts, improving risk models, and increasing public awareness of cognitive health monitoring. Sustained telehealth infrastructure investment supports continued remote assessment capabilities.
The digital cognitive screening platforms segment is expected to be the largest during the forecast period
The digital cognitive screening platforms segment is expected to account for the largest market share during the forecast period, due to their broad accessibility and established integration into primary care and community health settings. These platforms deliver brief, standardized cognitive assessments through tablets, smartphones, and web interfaces that require minimal staff training. Healthcare systems value the efficiency and cost-effectiveness of digital screening compared to traditional neuropsychological evaluation. Population health programs leverage these tools for large-scale dementia risk identification. The scalability of automated scoring and reporting supports enterprise deployment across health networks.
The artificial intelligence segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the artificial intelligence segment is predicted to witness the highest growth rate, driven by its capacity to analyze complex multi-modal data and identify subtle cognitive risk signatures invisible to traditional screening methods. Machine learning models trained on diverse datasets improve detection accuracy for early-stage neurodegenerative conditions. Natural language processing enables analysis of speech patterns for cognitive decline indicators. These AI capabilities significantly enhance screening sensitivity and specificity, reducing false positive rates that plague simpler digital assessments. Regulatory frameworks increasingly accommodate AI-based diagnostic software.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, due to advanced healthcare data infrastructure and established reimbursement for cognitive screening within Medicare annual wellness visits. The United States leads with substantial Alzheimer's research funding, major academic consortia generating large cognitive datasets, and favorable FDA regulatory pathways for software-based medical devices. Healthcare payers actively seek cost-effective early identification tools to manage dementia-related expenditures. Venture capital investment supports continuous innovation in digital cognitive assessment technologies.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly aging populations in China, Japan, and South Korea, creating urgent demand for dementia prevention infrastructure. Government digital health initiatives support technology adoption across public hospital networks. Growing middle-class health awareness drives consumer demand for cognitive health screening. The region's technology ecosystem enables indigenous platform development at competitive price points. Health insurance expansion in emerging markets increases patient access to preventive cognitive assessment services previously unavailable.
Key players in the market
Some of the key players in Digital Cognitive Risk Assessment Market include Cambridge Cognition Holdings plc, Cogstate Ltd., CNS Vital Signs, Creyos Corporation, Philips Healthcare, GE HealthCare, Siemens Healthineers AG, Canon Medical Systems Corporation, FUJIFILM Healthcare, Tempus AI, Verily Life Sciences, Oracle Health, IBM Corporation, Natus Medical Incorporated, Compumedics Limited, EMOTIV Inc. and BrainCo Inc..
Key Developments:
In June 2026, Cambridge Cognition Holdings plc launched a next-generation digital cognitive risk assessment platform featuring AI-driven pattern recognition that identifies subtle preclinical markers of dementia from brief smartphone-based cognitive tests.
In May 2026, Cogstate Ltd. expanded its digital cognitive screening portfolio to include population health analytics capabilities, enabling healthcare systems to identify geographic clusters of elevated dementia risk for targeted intervention deployment.
In April 2026, Creyos Corporation introduced a cloud-based cognitive risk assessment system designed for primary care integration that delivers immediate risk scores and automated referral recommendations based on standardized digital cognitive testing.
Solution Types Covered:
- Digital Cognitive Screening Platforms
- AI-Based Risk Assessment Software
- Clinical Decision Support Systems
- Digital Biomarker Platforms
- Remote Cognitive Monitoring Solutions
- Population Risk Assessment Platforms
- Artificial Intelligence
- Machine Learning
- Predictive Analytics
- Big Data Analytics
- Cloud Computing
- Digital Biomarkers
- Internet of Medical Things (IoMT)
- Dementia Risk Assessment
- Alzheimers Disease Screening
- Stroke Risk Evaluation
- Neurodegenerative Disease Screening
- Cognitive Impairment Detection
- Clinical Trial Participant Screening
- Population Health Risk Management
- Hospitals
- Diagnostic Centers
- Neurology Clinics
- Research Institutes
- Pharmaceutical Companies
- Healthcare Payers
- Other End Users
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Rest of the World (RoW)
- Middle East
- Saudi Arabia
- United Arab Emirates
- Qatar
- Israel
- Rest of Middle East
- Africa
- South Africa
- Egypt
- Morocco
- Rest of Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
1 EXECUTIVE SUMMARY
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL DIGITAL COGNITIVE RISK ASSESSMENT MARKET, BY SOLUTION TYPE
5.1 Digital Cognitive Screening Platforms
5.2 AI-Based Risk Assessment Software
5.3 Clinical Decision Support Systems
5.4 Digital Biomarker Platforms
5.5 Remote Cognitive Monitoring Solutions
5.6 Population Risk Assessment Platforms
6 GLOBAL DIGITAL COGNITIVE RISK ASSESSMENT MARKET, BY TECHNOLOGY
6.1 Artificial Intelligence
6.2 Machine Learning
6.3 Predictive Analytics
6.4 Big Data Analytics
6.5 Cloud Computing
6.6 Digital Biomarkers
6.7 Internet of Medical Things (IoMT)
7 GLOBAL DIGITAL COGNITIVE RISK ASSESSMENT MARKET, BY APPLICATION
7.1 Dementia Risk Assessment
7.2 Alzheimer's Disease Screening
7.3 Stroke Risk Evaluation
7.4 Neurodegenerative Disease Screening
7.5 Cognitive Impairment Detection
7.6 Clinical Trial Participant Screening
7.7 Population Health Risk Management
8 GLOBAL DIGITAL COGNITIVE RISK ASSESSMENT MARKET, BY END USER
8.1 Hospitals
8.2 Diagnostic Centers
8.3 Neurology Clinics
8.4 Research Institutes
8.5 Pharmaceutical Companies
8.6 Healthcare Payers
8.7 Other End Users
9 GLOBAL DIGITAL COGNITIVE RISK ASSESSMENT MARKET, BY GEOGRAPHY
9.1 North America
9.1.1 United States
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 United Kingdom
9.2.2 Germany
9.2.3 France
9.2.4 Italy
9.2.5 Spain
9.2.6 Netherlands
9.2.7 Belgium
9.2.8 Sweden
9.2.9 Switzerland
9.2.10 Poland
9.2.11 Rest of Europe
9.3 Asia Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 South Korea
9.3.5 Australia
9.3.6 Indonesia
9.3.7 Thailand
9.3.8 Malaysia
9.3.9 Singapore
9.3.10 Vietnam
9.3.11 Rest of Asia Pacific
9.4 South America
9.4.1 Brazil
9.4.2 Argentina
9.4.3 Colombia
9.4.4 Chile
9.4.5 Peru
9.4.6 Rest of South America
9.5 Rest of the World (RoW)
9.5.1 Middle East
9.5.1.1 Saudi Arabia
9.5.1.2 United Arab Emirates
9.5.1.3 Qatar
9.5.1.4 Israel
9.5.1.5 Rest of Middle East
9.5.2 Africa
9.5.2.1 South Africa
9.5.2.2 Egypt
9.5.2.3 Morocco
9.5.2.4 Rest of Africa
10 STRATEGIC MARKET INTELLIGENCE
10.1 Industry Value Network and Supply Chain Assessment
10.2 White-Space and Opportunity Mapping
10.3 Product Evolution and Market Life Cycle Analysis
10.4 Channel, Distributor, and Go-to-Market Assessment
11 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
11.1 Mergers and Acquisitions
11.2 Partnerships, Alliances, and Joint Ventures
11.3 New Product Launches and Certifications
11.4 Capacity Expansion and Investments
11.5 Other Strategic Initiatives
12 COMPANY PROFILES
12.1 Cambridge Cognition Holdings plc
12.2 Cogstate Ltd.
12.3 CNS Vital Signs
12.4 Creyos Corporation
12.5 Philips Healthcare
12.6 GE HealthCare
12.7 Siemens Healthineers AG
12.8 Canon Medical Systems Corporation
12.9 FUJIFILM Healthcare
12.10 Tempus AI
12.11 Verily Life Sciences
12.12 Oracle Health
12.13 IBM Corporation
12.14 Natus Medical Incorporated
12.15 Compumedics Limited
12.16 EMOTIV Inc.
12.17 BrainCo Inc.
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL DIGITAL COGNITIVE RISK ASSESSMENT MARKET, BY SOLUTION TYPE
5.1 Digital Cognitive Screening Platforms
5.2 AI-Based Risk Assessment Software
5.3 Clinical Decision Support Systems
5.4 Digital Biomarker Platforms
5.5 Remote Cognitive Monitoring Solutions
5.6 Population Risk Assessment Platforms
6 GLOBAL DIGITAL COGNITIVE RISK ASSESSMENT MARKET, BY TECHNOLOGY
6.1 Artificial Intelligence
6.2 Machine Learning
6.3 Predictive Analytics
6.4 Big Data Analytics
6.5 Cloud Computing
6.6 Digital Biomarkers
6.7 Internet of Medical Things (IoMT)
7 GLOBAL DIGITAL COGNITIVE RISK ASSESSMENT MARKET, BY APPLICATION
7.1 Dementia Risk Assessment
7.2 Alzheimer's Disease Screening
7.3 Stroke Risk Evaluation
7.4 Neurodegenerative Disease Screening
7.5 Cognitive Impairment Detection
7.6 Clinical Trial Participant Screening
7.7 Population Health Risk Management
8 GLOBAL DIGITAL COGNITIVE RISK ASSESSMENT MARKET, BY END USER
8.1 Hospitals
8.2 Diagnostic Centers
8.3 Neurology Clinics
8.4 Research Institutes
8.5 Pharmaceutical Companies
8.6 Healthcare Payers
8.7 Other End Users
9 GLOBAL DIGITAL COGNITIVE RISK ASSESSMENT MARKET, BY GEOGRAPHY
9.1 North America
9.1.1 United States
9.1.2 Canada
9.1.3 Mexico
9.2 Europe
9.2.1 United Kingdom
9.2.2 Germany
9.2.3 France
9.2.4 Italy
9.2.5 Spain
9.2.6 Netherlands
9.2.7 Belgium
9.2.8 Sweden
9.2.9 Switzerland
9.2.10 Poland
9.2.11 Rest of Europe
9.3 Asia Pacific
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 South Korea
9.3.5 Australia
9.3.6 Indonesia
9.3.7 Thailand
9.3.8 Malaysia
9.3.9 Singapore
9.3.10 Vietnam
9.3.11 Rest of Asia Pacific
9.4 South America
9.4.1 Brazil
9.4.2 Argentina
9.4.3 Colombia
9.4.4 Chile
9.4.5 Peru
9.4.6 Rest of South America
9.5 Rest of the World (RoW)
9.5.1 Middle East
9.5.1.1 Saudi Arabia
9.5.1.2 United Arab Emirates
9.5.1.3 Qatar
9.5.1.4 Israel
9.5.1.5 Rest of Middle East
9.5.2 Africa
9.5.2.1 South Africa
9.5.2.2 Egypt
9.5.2.3 Morocco
9.5.2.4 Rest of Africa
10 STRATEGIC MARKET INTELLIGENCE
10.1 Industry Value Network and Supply Chain Assessment
10.2 White-Space and Opportunity Mapping
10.3 Product Evolution and Market Life Cycle Analysis
10.4 Channel, Distributor, and Go-to-Market Assessment
11 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
11.1 Mergers and Acquisitions
11.2 Partnerships, Alliances, and Joint Ventures
11.3 New Product Launches and Certifications
11.4 Capacity Expansion and Investments
11.5 Other Strategic Initiatives
12 COMPANY PROFILES
12.1 Cambridge Cognition Holdings plc
12.2 Cogstate Ltd.
12.3 CNS Vital Signs
12.4 Creyos Corporation
12.5 Philips Healthcare
12.6 GE HealthCare
12.7 Siemens Healthineers AG
12.8 Canon Medical Systems Corporation
12.9 FUJIFILM Healthcare
12.10 Tempus AI
12.11 Verily Life Sciences
12.12 Oracle Health
12.13 IBM Corporation
12.14 Natus Medical Incorporated
12.15 Compumedics Limited
12.16 EMOTIV Inc.
12.17 BrainCo Inc.
LIST OF TABLES
Table 1 Global Digital Cognitive Risk Assessment Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Digital Cognitive Risk Assessment Market Outlook, By Solution Type (2023-2034) ($MN)
Table 3 Global Digital Cognitive Risk Assessment Market Outlook, By Digital Cognitive Screening Platforms (2023-2034) ($MN)
Table 4 Global Digital Cognitive Risk Assessment Market Outlook, By AI-Based Risk Assessment Software (2023-2034) ($MN)
Table 5 Global Digital Cognitive Risk Assessment Market Outlook, By Clinical Decision Support Systems (2023-2034) ($MN)
Table 6 Global Digital Cognitive Risk Assessment Market Outlook, By Digital Biomarker Platforms (2023-2034) ($MN)
Table 7 Global Digital Cognitive Risk Assessment Market Outlook, By Remote Cognitive Monitoring Solutions (2023-2034) ($MN)
Table 8 Global Digital Cognitive Risk Assessment Market Outlook, By Population Risk Assessment Platforms (2023-2034) ($MN)
Table 9 Global Digital Cognitive Risk Assessment Market Outlook, By Technology (2023-2034) ($MN)
Table 10 Global Digital Cognitive Risk Assessment Market Outlook, By Artificial Intelligence (2023-2034) ($MN)
Table 11 Global Digital Cognitive Risk Assessment Market Outlook, By Machine Learning (2023-2034) ($MN)
Table 12 Global Digital Cognitive Risk Assessment Market Outlook, By Predictive Analytics (2023-2034) ($MN)
Table 13 Global Digital Cognitive Risk Assessment Market Outlook, By Big Data Analytics (2023-2034) ($MN)
Table 14 Global Digital Cognitive Risk Assessment Market Outlook, By Cloud Computing (2023-2034) ($MN)
Table 15 Global Digital Cognitive Risk Assessment Market Outlook, By Digital Biomarkers (2023-2034) ($MN)
Table 16 Global Digital Cognitive Risk Assessment Market Outlook, By Internet of Medical Things (IoMT) (2023-2034) ($MN)
Table 17 Global Digital Cognitive Risk Assessment Market Outlook, By Application (2023-2034) ($MN)
Table 18 Global Digital Cognitive Risk Assessment Market Outlook, By Dementia Risk Assessment (2023-2034) ($MN)
Table 19 Global Digital Cognitive Risk Assessment Market Outlook, By Alzheimer's Disease Screening (2023-2034) ($MN)
Table 20 Global Digital Cognitive Risk Assessment Market Outlook, By Stroke Risk Evaluation (2023-2034) ($MN)
Table 21 Global Digital Cognitive Risk Assessment Market Outlook, By Neurodegenerative Disease Screening (2023-2034) ($MN)
Table 22 Global Digital Cognitive Risk Assessment Market Outlook, By Cognitive Impairment Detection (2023-2034) ($MN)
Table 23 Global Digital Cognitive Risk Assessment Market Outlook, By Clinical Trial Participant Screening (2023-2034) ($MN)
Table 24 Global Digital Cognitive Risk Assessment Market Outlook, By Population Health Risk Management (2023-2034) ($MN)
Table 25 Global Digital Cognitive Risk Assessment Market Outlook, By End User (2023-2034) ($MN)
Table 26 Global Digital Cognitive Risk Assessment Market Outlook, By Hospitals (2023-2034) ($MN)
Table 27 Global Digital Cognitive Risk Assessment Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
Table 28 Global Digital Cognitive Risk Assessment Market Outlook, By Neurology Clinics (2023-2034) ($MN)
Table 29 Global Digital Cognitive Risk Assessment Market Outlook, By Research Institutes (2023-2034) ($MN)
Table 30 Global Digital Cognitive Risk Assessment Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
Table 31 Global Digital Cognitive Risk Assessment Market Outlook, By Healthcare Payers (2023-2034) ($MN)
Table 32 Global Digital Cognitive Risk Assessment Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
Table 1 Global Digital Cognitive Risk Assessment Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Digital Cognitive Risk Assessment Market Outlook, By Solution Type (2023-2034) ($MN)
Table 3 Global Digital Cognitive Risk Assessment Market Outlook, By Digital Cognitive Screening Platforms (2023-2034) ($MN)
Table 4 Global Digital Cognitive Risk Assessment Market Outlook, By AI-Based Risk Assessment Software (2023-2034) ($MN)
Table 5 Global Digital Cognitive Risk Assessment Market Outlook, By Clinical Decision Support Systems (2023-2034) ($MN)
Table 6 Global Digital Cognitive Risk Assessment Market Outlook, By Digital Biomarker Platforms (2023-2034) ($MN)
Table 7 Global Digital Cognitive Risk Assessment Market Outlook, By Remote Cognitive Monitoring Solutions (2023-2034) ($MN)
Table 8 Global Digital Cognitive Risk Assessment Market Outlook, By Population Risk Assessment Platforms (2023-2034) ($MN)
Table 9 Global Digital Cognitive Risk Assessment Market Outlook, By Technology (2023-2034) ($MN)
Table 10 Global Digital Cognitive Risk Assessment Market Outlook, By Artificial Intelligence (2023-2034) ($MN)
Table 11 Global Digital Cognitive Risk Assessment Market Outlook, By Machine Learning (2023-2034) ($MN)
Table 12 Global Digital Cognitive Risk Assessment Market Outlook, By Predictive Analytics (2023-2034) ($MN)
Table 13 Global Digital Cognitive Risk Assessment Market Outlook, By Big Data Analytics (2023-2034) ($MN)
Table 14 Global Digital Cognitive Risk Assessment Market Outlook, By Cloud Computing (2023-2034) ($MN)
Table 15 Global Digital Cognitive Risk Assessment Market Outlook, By Digital Biomarkers (2023-2034) ($MN)
Table 16 Global Digital Cognitive Risk Assessment Market Outlook, By Internet of Medical Things (IoMT) (2023-2034) ($MN)
Table 17 Global Digital Cognitive Risk Assessment Market Outlook, By Application (2023-2034) ($MN)
Table 18 Global Digital Cognitive Risk Assessment Market Outlook, By Dementia Risk Assessment (2023-2034) ($MN)
Table 19 Global Digital Cognitive Risk Assessment Market Outlook, By Alzheimer's Disease Screening (2023-2034) ($MN)
Table 20 Global Digital Cognitive Risk Assessment Market Outlook, By Stroke Risk Evaluation (2023-2034) ($MN)
Table 21 Global Digital Cognitive Risk Assessment Market Outlook, By Neurodegenerative Disease Screening (2023-2034) ($MN)
Table 22 Global Digital Cognitive Risk Assessment Market Outlook, By Cognitive Impairment Detection (2023-2034) ($MN)
Table 23 Global Digital Cognitive Risk Assessment Market Outlook, By Clinical Trial Participant Screening (2023-2034) ($MN)
Table 24 Global Digital Cognitive Risk Assessment Market Outlook, By Population Health Risk Management (2023-2034) ($MN)
Table 25 Global Digital Cognitive Risk Assessment Market Outlook, By End User (2023-2034) ($MN)
Table 26 Global Digital Cognitive Risk Assessment Market Outlook, By Hospitals (2023-2034) ($MN)
Table 27 Global Digital Cognitive Risk Assessment Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
Table 28 Global Digital Cognitive Risk Assessment Market Outlook, By Neurology Clinics (2023-2034) ($MN)
Table 29 Global Digital Cognitive Risk Assessment Market Outlook, By Research Institutes (2023-2034) ($MN)
Table 30 Global Digital Cognitive Risk Assessment Market Outlook, By Pharmaceutical Companies (2023-2034) ($MN)
Table 31 Global Digital Cognitive Risk Assessment Market Outlook, By Healthcare Payers (2023-2034) ($MN)
Table 32 Global Digital Cognitive Risk Assessment Market Outlook, By Other End Users (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
